Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment

NEXT STORY
OpGen to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
PREV STORY
HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Delcath Issues Letter to Shareholders

NEW YORK, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional ...

author_avatar
NASDAQ Market News

FallCall App adopts Siri Shortcuts: Use your voice to contact family and emergency call center via Apple Watch, iPhone and HomePod

TRUMBULL, CT, Nov. 21, 2018 (GLOBE NEWSWIRE) -- FallCall Solutions announced today that FallCall™ ...

author_avatar
NASDAQ Market News

NGS Sample Preparation Market Size To Reach USD 5.42 Billion In 2028; Next-generation sequencing aids in more precise analysis of DNA and RNA sequencing as compared to other conventional sequencing methods, Says Reports And Data

author_avatar
NASDAQ Market News